Real Option Value and Path Dependence in Oncology Innovation

Joseph P Cook

Seminar Briefing from Office of Health Economics

Abstract: Based on an OHE Lunchtime Seminar, this publication addresses a persistent issue: how to adequately reward innovation through the pricing of new medicines given the limitations of the information available at launch. As the author points out, oncology drugs in particular often follow the path of incremental innovation, proceeding in steps towards realising their full potential in treatment -- and even cure. The publication describes the importance of taking future value into consideration in the initial assessment to encourage and spur progress in innovation. The perspectives of the innovative company and the patient are discussed as well the implications for cost-effectiveness and comparative-effectiveness assessments.

Keywords: Real; Option; Value; and; Path; Dependence; in; Oncology; Innovation (search for similar items in EconPapers)
JEL-codes: I1 (search for similar items in EconPapers)
Date: 2014-04-01
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.ohe.org/publications/real-option-value ... ion-value-cook-2014/ (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ohe:sembri:000077

Access Statistics for this paper

More papers in Seminar Briefing from Office of Health Economics Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ( this e-mail address is bad, please contact ).